公开(公告)号：US20240059673A1

公开(公告)日：2024-02-22

申请号：US18268440

申请日：2021-12-21

Applicant: Gilead Sciences, Inc.

Inventor： Stephen E. Ammann ,  Eda Y. Canales ,  Weng K. Chang ,  Scott E. Lazerwith ,  Daniel G. Shore

IPC: C07D401/14 ,  A61K45/06 ,  C07D471/04 ,  C07D413/14 ,  C07D401/04 ,  A61K31/496 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4375

CPC classification number: C07D401/14 ,  A61K45/06 ,  C07D471/04 ,  C07D413/14 ,  C07D401/04 ,  A61K31/496 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4375

Abstract: The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of an autoimmune disease and/or inflammatory condition, including systemic lupus erythematosus and cutaneous lupus erythematosus.

公开(公告)号：US20230312567A1

公开(公告)日：2023-10-05

申请号：US18110126

申请日：2023-02-15

Applicant: Gilead Sciences, Inc.

Inventor： Chienhung Chou ,  Darryl Kato ,  Scott E. Lazerwith ,  John O. Link ,  Scott D. Schroeder ,  Winston C. Tse ,  Jennifer R. Zhang

IPC: C07D471/04 ,  A61K45/06 ,  C07D403/12 ,  C07D498/04 ,  C07D513/04 ,  C07D519/00

CPC classification number: C07D471/04 ,  A61K45/06 ,  C07D403/12 ,  C07D498/04 ,  C07D513/04 ,  C07D519/00

Abstract: The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of a Retroviridae viral infection, including an infection caused by the HIV virus.

公开(公告)号：US20230270734A1

公开(公告)日：2023-08-31

申请号：US17930538

申请日：2022-09-08

Applicant: Gilead Sciences, Inc.

Inventor： Stephen E. Ammann ,  Eda Y. Canales ,  Weng K. Chang ,  Henok H. Kinfe ,  Scott E. Lazerwith ,  Michael L. Mitchell ,  Yasamin Moazami ,  Scott D. Schroeder ,  Daniel G. Shore

IPC: A61K31/4545 ,  A61K45/06 ,  A61K31/4706 ,  C07D519/00 ,  A61K31/439 ,  A61K31/437 ,  A61K31/496 ,  A61K31/5377

CPC classification number: A61K31/4545 ,  A61K45/06 ,  A61K31/4706 ,  C07D519/00 ,  A61K31/439 ,  A61K31/437 ,  A61K31/496 ,  A61K31/5377

Abstract: The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of an autoimmune disease and/or inflammatory condition, including systemic lupus erythematosus and cutaneous lupus erythematosus.

公开(公告)号：US20230270719A1

公开(公告)日：2023-08-31

申请号：US18059806

申请日：2022-11-29

Applicant: Gilead Sciences, Inc.

Inventor： Jinfa Du ,  Joshua A. Kaplan ,  Thorsten A. Kirschberg ,  Tetsuya Kobayashi ,  Scott E. Lazerwith ,  Rick Andrew Lee ,  Jonathan William Medley ,  Michael L. Mitchell ,  Philip Anthony Morganelli ,  Hyung-Jung Pyun ,  Sophia L. Shevick ,  Neil H. Squires ,  William J. Watkins

IPC: A61K31/403 ,  C07D487/04 ,  C07D519/00 ,  A61P31/20 ,  A61K31/03 ,  A61K31/16 ,  A61K31/38 ,  A61K31/4192

CPC classification number: A61K31/403 ,  C07D487/04 ,  C07D519/00 ,  A61P31/20 ,  A61K31/03 ,  A61K31/16 ,  A61K31/38 ,  A61K31/4192

Abstract: This application relates generally to certain substituted pyrrolizine compounds, and pharmaceutical compositions which inhibit HBV replication, and methods of making and using them.

公开(公告)号：US20230148157A1

公开(公告)日：2023-05-11

申请号：US17862896

申请日：2022-07-12

Applicant: Gilead Sciences, Inc.

Inventor： David Alan Gutierrez ,  Tetsuya Kobayashi ,  Scott E. Lazerwith ,  Rick Andrew Lee ,  Philip Anthony Morganelli ,  Hyung-Jung Pyun

IPC: C07D487/04 ,  A61P31/20

CPC classification number: C07D487/04 ,  A61P31/20

Abstract: This application relates generally to certain substituted pyrrolizine compounds, and pharmaceutical compositions which inhibit HBV replication, and methods of making and using them.

公开(公告)号：US11548901B2

公开(公告)日：2023-01-10

申请号：US16868119

申请日：2020-05-06

Applicant: Gilead Sciences, Inc.

Inventor： Elizabeth M. Bacon ,  Zhenhong R. Cai ,  Xiaowu Chen ,  Jeromy J. Cottell ,  Manoj C. Desai ,  Mingzhe Ji ,  Haolun Jin ,  Scott E. Lazerwith ,  Michael R. Mish ,  Philip Anthony Morganelli ,  Hyung-Jung Pyun ,  James G. Taylor ,  Teresa Alejandra Trejo Martin

IPC: A61K31/4985 ,  C07D487/14 ,  C07D498/14 ,  A61K31/537 ,  C07D471/22 ,  A61K31/529 ,  A61K31/551 ,  A61K31/498 ,  C07D471/18 ,  A61K45/06 ,  C07D498/18 ,  A61K31/553

Abstract: Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, X, W, Y1, Y2, Z1, and Z4 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

公开(公告)号：US20220389034A1

公开(公告)日：2022-12-08

申请号：US17721636

申请日：2022-04-15

Applicant: Gilead Sciences, Inc.

Inventor： Stephen E. Ammann ,  Eda Y. Canales ,  Weng K. Chang ,  Henok H. Kinfe ,  Scott E. Lazerwith ,  Michael L. Mitchell ,  Yasamin Moazami ,  Scott D. Schroeder ,  Daniel G. Shore ,  Christopher J. Swank

IPC: C07D519/00 ,  C07D495/04

Abstract: The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of an autoimmune disease and/or inflammatory condition, including systemic lupus erythematosus and cutaneous lupus erythematosus.

公开(公告)号：US11420974B2

公开(公告)日：2022-08-23

申请号：US17070236

申请日：2020-10-14

Applicant: GILEAD SCIENCES, INC.

Inventor： David Alan Gutierrez ,  Tetsuya Kobayashi ,  Scott E. Lazerwith ,  Rick Andrew Lee ,  Philip Anthony Morganelli ,  Hyung-Jung Pyun

IPC: C07D487/04 ,  A61P31/20

Abstract: This application relates generally to certain substituted pyrrolizine compounds, and pharmaceutical compositions which inhibit HBV replication, and methods of making and using them.

公开(公告)号：US20220081455A1

公开(公告)日：2022-03-17

申请号：US17409261

申请日：2021-08-23

Applicant: Gilead Sciences, Inc.

Inventor： Scott E. Lazerwith ,  Jonathan William Medley ,  Philip A. Morganelli ,  Devan Naduthambi ,  Thomas P. Stratton ,  Peiyuan Wang

IPC: C07F9/6561

Abstract: Compounds and methods of using said compounds, singly or in combination with additional agents, and pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.

公开(公告)号：US11202780B2

公开(公告)日：2021-12-21

申请号：US16740174

申请日：2020-01-10

Applicant: Gilead Sciences, Inc.

Inventor： Ernest A. Carra ,  Irene Chen ,  Katie Ann Keaton ,  Scott E. Lazerwith ,  Vahid Zia

IPC: A61K31/5365 ,  C07D498/18 ,  A61K45/06 ,  A61K9/20 ,  C07D498/14 ,  A61K31/513 ,  A61K31/553 ,  A61K31/675 ,  A61K31/683 ,  A61K31/537

Abstract: The present invention relates to crystalline forms and co-crystals of (2R,5S,13aR)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide, the pharmaceutical formulations, and the therapeutic uses thereof. The present invention also relates to novel crystalline forms of sodium (2R,5S,13aR)-7,9-dioxo-10-(2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepin-8-olate Form I.